CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
Hee-Jeong Cho, Sang-Kyung Seo, Dong Won Baek, Sung-Woo Park, Yoo-Jin Lee, Sang-Kyun Sohn, Ho-Sup Lee, Won Sik Lee, Ji Hyun Lee, Sung Hyun Kim, Joon-Ho Moon
Yeungnam Univ J Med. 2018;35(1):76-83.   Published online June 30, 2018
DOI: https://doi.org/10.12701/yujm.2018.35.1.76

Excel Download

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
Yeungnam University Journal of Medicine. 2018;35(1):76-83   Crossref logo
Link1 Link2 Link3

Outcomes between frontline and salvage bortezomib-based regimens in elderly patients with multiple myeloma
Clinical Lymphoma Myeloma and Leukemia. 2015;15:e263   Crossref logo
Link1 Link2

Clinical impact of depth of response on 3 months after starting chemotherapy and cumulative dose of bortezomib on survival in elderly patients with multiple myeloma who treated with bortezomib combined melphalan plus prednisolone; How to improve survival rates by longer duration of treatment and early deeper response
Clinical Lymphoma Myeloma and Leukemia. 2015;15:e74   Crossref logo
Link1 Link2

Once-Weekly 1.6 mg/m2 Bortezomib BCD Regimen in Elderly Patients with Newly Diagnosed Multiple Myeloma Who are Unfit for Standard Dose Chemotherapy
Indian Journal of Hematology and Blood Transfusion. 2016;33(1):22-30   Crossref logo
Link1 Link2 Link3 Link4

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
Patient Preference and Adherence. 2014;939   Crossref logo
Link1

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
Journal of Translational Medicine. 2010;8(1):   Crossref logo
Link1 Link2 Link3

Frontline treatment of multiple myeloma in elderly patients
Blood Reviews. 2008;22(6):303-309   Crossref logo
Link1 Link2

Prognostic value of the inverse platelet-to-lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated upfront with a novel-agent-containing regimen
Clinical Lymphoma Myeloma and Leukemia. 2015;15:e112   Crossref logo
Link1 Link2

Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone
Annals of Hematology. 2016;96(3):461-467   Crossref logo
Link1 Link2 Link3

Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial
Clinical Lymphoma and Myeloma. 2008;8(5):315-317   Crossref logo
Link1 Link2